Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369280 | 0.81 | CES2 (0.59) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL29200055 | 0.81 | PTPN1 (0.56) | CES2SRD5A2ALDH1A1MAPT | |
| SCHEMBL7336597 | 0.80 | CES2 (0.57) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL29953080 | 0.80 | CES2 (0.61) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL4974507 | 0.80 | CES2 (0.61) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL27343169 | 0.79 | CES2 (0.56) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL30758861 | 0.79 | CES2 (0.69) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL1712437 | 0.77 | CES2 (0.67) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL2073691 | 0.77 | ACHE (0.72) | CES2NPSR1CTNNB1WNT3ASRD5A2 | |
| SCHEMBL2543135 | 0.77 | CES2 (0.53) | CES2NPSR1CTNNB1WNT3ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | CES2 4215/4885NPSR1 4800/4885CTNNB1 1184/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | CES2 4215/4885NPSR1 4800/4885CTNNB1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.